- Orexo AB (ORXOY, Financial) has announced successful proof-of-concept data for a powder-based intranasal vaccine using AmorphOX technology.
- The vaccine demonstrated strong antibody responses with both liquid and powder formulations in animal tests.
- AmorphOX technology offers potential benefits, including cost-efficiency and no cold chain requirements.
Orexo AB (ORXOY) has reported positive results from an in-vivo proof-of-concept study for its powder-based intranasal vaccine developed using the proprietary AmorphOX technology. Conducted in collaboration with Abera Bioscience, the study tested an influenza vaccine candidate in rats, utilizing both liquid nasal solution and intranasal powder formulations.
The test results showed that both delivery methods successfully induced strong systemic antibody responses in serum (IgG) and locally in the nose and lungs (IgA). Interestingly, there was no difference in immune response between the liquid and powder formulations. The use of AmorphOX technology in the powder formulation presents several advantages, such as reduced costs, increased thermostability, and the elimination of cold chain storage requirements.
This technological advancement could significantly impact future pandemic scenarios by simplifying logistics and potentially allowing self-administration during mass vaccination campaigns. The collaboration with Abera Bioscience, initiated in December 2024, aims to develop vaccines by integrating Orexo's AmorphOX technology with Abera's BERAâ„¢ platform.
Robert Rönn, SVP and Head of R&D at Orexo, highlighted the potential global reach of powder-based formulations, emphasizing their significant advantages in terms of logistics and thermal stability. Mats Lundgren, CSO of Abera Bioscience, noted the promising results, stating that both liquid and powder forms of the vaccines performed well, suggesting a valuable role for these formulations in pandemic preparedness.
